Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria-Victoria Mateos

Showing results (91-100 of 231) with videos related to

Pageof 24
Sort By:
The Lancet. Oncology|December 6, 2021
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 studySaad Z Usmani, Hang Quach, Maria-Victoria Mateos, et al.
European Journal of Haematology|July 12, 2024
An open-label, first-in-human, single agent, dose escalation study for the evaluation of safety and efficacy of SAR442085 in patients with relapsed or refractory multiple myelomaPrashant Kapoor, Nitya Nathwani, Tomas Jelinek, et al.
Haematologica|August 23, 2023
Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myelomaPaul G Richardson, Brian G Durie, Laura Rosiñol, et al.
European Journal of Haematology|September 30, 2010
Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA studyMeletios A Dimopoulos, Maria-Victoria Mateos, Paul G Richardson, et al.
Blood|July 5, 2019
Subcutaneous delivery of daratumumab in relapsed or refractory multiple myelomaSaad Z Usmani, Hareth Nahi, Maria-Victoria Mateos, et al.
Journal of Cancer Research and Clinical Oncology|August 28, 2020
Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. intravenous for relapsed or refractory multiple myeloma: COLUMBA clinical trial resultsSaad Z Usmani, Maria-Victoria Mateos, Vania Hungria, et al.
Haematologica|March 1, 2024
Health-related quality of life in relapsed/refractory multiple myeloma treated with melflufen and dexamethasone: analyses from the phase III OCEAN studyFredrik H Schjesvold, Heinz Ludwig, Sossana Delimpasi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2022
Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III TrialPieter Sonneveld, Asher Chanan-Khan, Katja Weisel, et al.
Leukemia|May 19, 2021
Survival prediction and treatment optimization of multiple myeloma patients using machine-learning models based on clinical and gene expression dataAdrián Mosquera Orgueira, Marta Sonia González Pérez, José Ángel Díaz Arias, et al.
Haematologica|May 2, 2020
Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO)Jesus San-Miguel, Saad Z Usmani, Maria-Victoria Mateos, et al.
Pageof 24

Showing results (91-100 of 231) with videos related to

Sort By:
Pageof 24
The Lancet. Oncology|December 6, 2021
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 studySaad Z Usmani, Hang Quach, Maria-Victoria Mateos, et al.
European Journal of Haematology|July 12, 2024
An open-label, first-in-human, single agent, dose escalation study for the evaluation of safety and efficacy of SAR442085 in patients with relapsed or refractory multiple myelomaPrashant Kapoor, Nitya Nathwani, Tomas Jelinek, et al.
Haematologica|August 23, 2023
Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myelomaPaul G Richardson, Brian G Durie, Laura Rosiñol, et al.
European Journal of Haematology|September 30, 2010
Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA studyMeletios A Dimopoulos, Maria-Victoria Mateos, Paul G Richardson, et al.
Blood|July 5, 2019
Subcutaneous delivery of daratumumab in relapsed or refractory multiple myelomaSaad Z Usmani, Hareth Nahi, Maria-Victoria Mateos, et al.
Journal of Cancer Research and Clinical Oncology|August 28, 2020
Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. intravenous for relapsed or refractory multiple myeloma: COLUMBA clinical trial resultsSaad Z Usmani, Maria-Victoria Mateos, Vania Hungria, et al.
Haematologica|March 1, 2024
Health-related quality of life in relapsed/refractory multiple myeloma treated with melflufen and dexamethasone: analyses from the phase III OCEAN studyFredrik H Schjesvold, Heinz Ludwig, Sossana Delimpasi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2022
Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III TrialPieter Sonneveld, Asher Chanan-Khan, Katja Weisel, et al.
Leukemia|May 19, 2021
Survival prediction and treatment optimization of multiple myeloma patients using machine-learning models based on clinical and gene expression dataAdrián Mosquera Orgueira, Marta Sonia González Pérez, José Ángel Díaz Arias, et al.
Haematologica|May 2, 2020
Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO)Jesus San-Miguel, Saad Z Usmani, Maria-Victoria Mateos, et al.
Pageof 24